Skip to main content

Table 3 Cumulative biodistribution data of [ 111 In]AT2S in AR4-2J and HEK293-hsst 2A + , -hsst 3 + , and -hsst 5 + tumor-bearing SCID mice

From: [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study

[111In]AT2S (%ID/g tissue ± SD)
Organs AR4-2J HEK293-hsst 2A + HEK293-hsst 3 + HEK293-hsst 5 +
  1 h 4 h 4 h + Tate a 4 h 4 h + DP2 b 4 h 4 h + AT2S c 4 h 4 h + AT2S c
Blood 1.34 ± 0.21 0.19 ± 0.02 0.26 ± 0.03 0.23 ± 0.07 0.66 ± 0.35 0.19 ± 0.03 0.2 ± 0.10 0.1 ± 0.04 0.23 ± 0.03
Liver 1.27 ± 0.09 0.95 ± 0.21 1.02 ± 0.11 1.31 ± 0.36 0.963 ± 0.67 1.02 ± 0.19 1.09 ± 0.2 1.1 ± 0.08 1.25 ± 0.09
Heart 0.67 ± 0.12 0.18 ± 0.05 0.17 ± 0.04 0.22 ± 0.05 0.38 ± 0.10 0.15 ± 0.04 0.15 ± 0.01 0.15 ± 0.02 0.18 ± 0.03
Kidneys 23.83 ± 4.28 21.10 ± 4.43 24.41 ± 9.15 23.20 ± 7.04 25.51 ± 3.70 23.42 ± 4.69 23.55 ± 8.96 24.12 ± 1.21 24.68 ± 2.20
Stomach 3.23 ± 0.77 1.81 ± 0.47 0.18 ± 0.07*** 1.96 ± 0.53 1.29 ± 0.36 3.41 ± 0.97 0.19 ± 0.05*** 3.06 ± 0.73 0.17 ± 0.2***
Intestines 1.98 ± 0.29 1.92 ± 0.25 0.77 ± 0.58* 2.00 ± 0.48 1.74 ± 1.02 2.39 ± 0.43 0.54 ± 0.2*** 1.54 ± 0.09 0.57 ± 0.20***
Spleen 0.84 ± 0.21 1.10 ± 0.63 0.61 ± 0.18 0.46 ± 0.11 0.50 ± 0.36 0.82 ± 0.11 0.98 ± 0.23 0.78 ± 0.07 1.08 ± 0.16
Muscle 0.22 ± 0.02 0.06 ± 0.01 0.07 ± 0.01 0.07 ± 0.02 0.07 ± 0.03 0.06 ± 0.01 0.07 ± 0.02 0.06 ± 0.01 0.06 ± 0.02
Lung 2.05 ± 0.52 1.43 ± 1.36 3.30 ± 4.93 1.37 ± 0.55 0.47 ± 0.08 0.68 ± 0.29 0.73 ± 0.14 0.56 ± 0.28 0.83 ± 0.13
Femur 0.49 ± 0.12 0.40 ± 0.24 0.19 ± 0.02 0.24 ± 0.09 0.21 ± 0.11 0.23 ± 0.03 0.23 ± 0.04 - -
Pancreas 7.35 ± 0.74 5.13 ± 0.75 0.15 ± 0.05** 5.73 ± 1.28 0.16 ± 0.10*** 3.33 ± 0.4 0.11 ± 0.01*** 2.79 ± 0.4 0.43 ± 0.54***
Tumor 3.05 ± 0.51 1.82 ± 0.36 0.21 ± 0.17*** 1.49 ± 0.2 0.27 ± 0.20*** 1.24 ± 0.27 0.32 ± 0.06*** 0.41 ± 0.12 0.22 ± 0.006*
  1. *Significant (p < 0.05), and ** and ***highly significant (p < 0.005) difference between blocked and unblocked animals (Student’s t test). aCo-injection of 50 nmol Tate; bco-injection of 35 nmol DP2; cco-injection of 35 nmol AT2S.